Drugs / ASC50
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07024602 | Jun 2025 → Jun 2026 overdue | psoriasis | Ascletis Pharma Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-15 | Ascletis Pharmaceuticals Co., Ltd. | Results 歌礼宣布有望成为同类最佳口服小分子IL-17抑制剂ASC50美国I期研究取得积极的顶线结果 ascletis.com ↗
ASC50 demonstrated a dose-proportional pharmacokinetic profile from 10 mg to 600 mg. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-15 | Ascletis Pharmaceuticals Co., Ltd. | 歌礼宣布有望成为同类最佳口服小分子IL-17抑制剂ASC50美国I期研究取得积极的顶线结果 ascletis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASC50 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07024602 ↗ |
| Route | Oral | “Drug: ASC50 administered orally” NCT07024602 ↗ |